Advertisement

Critical role of macrophage migration inhibitory factor in sepsis via interfere with MCP-1/CCL2 signaling pathway

[Limited Access]      HTML         Full Text-PDF

American Journal of BioMedicine  Volume 2, Issue 6, pages 688-701, June 2014


Jason J Goodman; Alison A Putensen; Richard H Calandra; John C Dios; Guosheng Bacher; Smith G Tracey

Abstract

Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by the multiple cell types, modulates the expression of several inflammatory molecules. Since MIF is a critical mediator of septic shock by modulation of innate immune responses and many studies demonstrated the role of MIF in sepsis pathogenesis and signaling pathways; however, the mechanisms underlying these changes remain unclear. MIF also promotes the migration and recruitment of immune cells inducing the expression of chemokines (monocyte chemoattractant protein (MCP)-1, adhesion molecules as intercellular adhesion molecule (I-CAM)-1 and vascular cell adhesion molecule (V-CAM)-1. Male  MIF+/+ and MIF−/− mice were subjected to cecal ligation and puncture (CLP) to induce sepsis.  Mif(-/-) mice had enhanced susceptibility to bacterial infections and impaired tumor necrosis factor (TNF) compared with MIF+/+. Further, Mif(-/-) mice showed upregulation of proinflammatory cytokine and eleveated the levels of MCP-1. Interesting treatment with recombinant human MIF (rhMIF) before CLP protected the animals from sepsis. Together, these data suggest that potential of targeting or exploiting MIF for therapeutic strategies in the management of sepsis.

Keywords: Macrophage migration inhibitory factor; Sepsis; Proinflammatory cytokine; MCP-1; Recombinant human MIF


References

1. Cvetkovic I. et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology. 2005;146(7):2942–51. [PubMed]

2. Mizue Y, Ghani S, Leng L. et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 2005;102(40):14410–5. [PubMed]

3. Lin S.G, Yu XY, Chen YX. et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 2000;87(12):1202–8. [PubMed]

4. Boyce N.W, Tipping PG, Holdsworth SR. Lymphokine (MIF) production by glomerular T-lymphocytes in experimental glomerulonephritis. Kidney Int 1986;30(5):673–7. [PubMed]

5. Matsui Y, Okamoto H, Jia N. et al. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. J Mol Cell Cardiol 2004;37(2):557–66. [PubMed]

6. Pollak N, Sterns T, Echtenacher B. et al. Improved resistance to bacterial superinfection in mice by treatment with macrophage migration inhibitory factor. Infect Immun 2005;73(10):6488–92. [PubMed]

7. Yabunaka N, Nishihira J, Mizue Y. et al. Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000;23(2):256–8. [PubMed]

8. Sprong T. et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 2007;27(5):482–7. [PubMed]

9. Mitchell RA, Liao H, Chesney J. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci USA 2002;99(1):345–50. [PubMed]

10.  Austin EW, Yousif NG, Ao L, Fullerton DA, Meng X. Ghrelin reduces myocardial injury following global ischemia and reperfusion via suppression of myocardial inflammatory response. American journal of BioMedicine; 1(2):38-48. [Abstarct/Full-Text]

11. Malu D.T, Bélanger B, Desautels F. et al. Macrophage migration inhibitory factor: a downregulator of early T cell-dependent IFN-gamma responses in Plasmodium chabaudi adami (556 KA)-infected mice. J Immunol 2011;186(11):6271–9. [PubMed]

12. De Mast Q, Sweep FC, McCall M. et al. A decrease of plasma macrophage migration inhibitory factor concentration is associated with lower numbers of circulating lymphocytes in experimental Plasmodium falciparum malaria. Parasite Immunol 2008;30(3):133–8. [PubMed]

13. Barton A. et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun 2003;4(7):487–91. [PubMed]

14. Amoli M.M, Donn RP, Thomson W. et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. J Rheumatol 2002;29(8):1671–3. [PubMed]

15. Wang J, Juan JD, Miravalle DH, MacLean K, et al. Role of macrophage SR-BI class a scavenger receptor in atherosclerosis: Crosstalk TLR4/NF-KB/ signaling pathway activation. American journal of BioMedicine; 2(1): 94–112. [Abstarct/Full-Text]

16. Angus DC, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310. [PubMed]

17. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207–214. [PubMed]

18. Underhill DM, Ozinsky A. Phagocytosis of microbes: Complexity in action. Annu Rev Immuno 2002;20:825–852. [PubMed]

19. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704. [PubMed]

20. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH. Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor). Circ Shock 1992;36:191–199. [PubMed]

21. Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. Drug News Perspect 2005;18:417–426. [PubMed]

22. Noels H, Bernhagen J, Weber C. Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. Trends Cardiovasc Med 2009;19:76–86. [PubMed]

23. Lin SG, Yu XY, Chen YX, Huang XR, Metz C, Bucala R, et al. De novo expression of macrophage migration inhibitory factor in atherogenesis in rabbits. Circ Res 2000;87:1202–1208. [Abstract/FREE Full Text]

24. Yu CM, Lai KW, Chen YX, Huang XR, Lan HY. Expression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J Histochem Cytochem 2003;51:625–631. [Abstract/FREE Full Text]

25. Kanzler I,Tuchscheerer N, Steffens G, Simsekyilmaz S, Konschalla S, Kroh A,et al. Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis. Basic Res Cardiol 2013;108:310. [PubMed]

26. Gregory JL, Morand EF, McKeown SJ, Ralph JA, Hall P, Yang YH, et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 2006;177:8072–8079. [Abstract/FREE Full Text]

27. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T, et al. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005;96:881–889. [Abstract/FREE Full Text]

28. Yousif NG, FG Al-amran FG. Novel Toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC cardiovascular disorders 2011;11(1):62. [Abstract/FREE Full Text]

29. Heinrichs D, Knauel M, Offermanns C, Berres ML, Nellen A, Leng L, et al. Macrophage migration inhibitory factor (MIF) exerts antifibrotic effects in experimental liver fibrosis via CD74. Proc Natl Acad Sci USA 2011;108:17444–17449. [Abstract/FREE Full Text]

30. Koga K, Kenessey A, Ojamaa K. Macrophage migration inhibitory factor antagonizes pressure overload-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol  2013;304:H282–H293. [Abstract/FREE Full Text]

31. Liehn EA, Merx MW, Postea O, Becher S, Djalali-Talab Y, Shagdarsuren E,Weber C, et al. Ccr1 deficiency reduces inflammatory remodelling and preserves left ventricular function after myocardial infarction. J Cell Mol Med 2008;12:496–506. [PubMed]

32. Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T, et al. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007;115:584–592. [Abstract/FREE Full Text]

33. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121–1127. [PubMed]

34. Yamamoto T, Eckes B, Mauch C, Hartmann K, Krieg T. Monocyte chemoattractant protein-1 enhances gene expression and synthesis of matrix metalloproteinase-1 in human fibroblasts by an autocrine IL-1 alpha loop. J Immunol 2000; 164: 6174–6179. [Abstract/FREE Full Text]

35. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circulation Res 2004; 94: 1543–1553. [Abstract/FREE Full Text]

36. Ikonomidis JS, Hendrick JW, Parkhurst AM, Herron AR, Escobar PG, Dowdy KB, Stroud RE, Hapke E, Zile MR, Spinale FG. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 2005; 288: H149–H158. [Abstract/FREE Full Text]

37. Pollak N, Sterns T, Echtenacher B, Männel DN. Improved Resistance to Bacterial Superinfection in Mice by Treatment with Macrophage Migration Inhibitory Factor. Infect. Immun 2005 ;73 (10): 6488-6492. [Abstract/FREE Full Text]

American Journal of Biomedicine © 2017 Frontier Theme
%d bloggers like this: